Stryker Corporation (NYSE:SYK) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Stryker Corporation (NYSE:SYK) have been assigned an average recommendation of “Moderate Buy” from the twenty-two analysts that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $395.3333.

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. cut their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. Needham & Company LLC cut their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research note on Friday, May 1st. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $465.00 target price on shares of Stryker in a research note on Wednesday, March 4th.

Stryker Stock Performance

Shares of SYK stock opened at $312.14 on Friday. The company’s fifty day simple moving average is $316.40 and its 200-day simple moving average is $343.97. Stryker has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a market cap of $119.66 billion, a PE ratio of 36.13, a P/E/G ratio of 1.97 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the prior year, the business posted $2.84 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts anticipate that Stryker will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Stryker

Large investors have recently added to or reduced their stakes in the company. Sankala Group LLC acquired a new stake in Stryker during the 4th quarter valued at $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker during the 4th quarter worth $26,000. United Financial Planning Group LLC acquired a new position in Stryker during the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker during the 4th quarter worth $27,000. Finally, DJE Kapital AG acquired a new position in Stryker during the 4th quarter worth $28,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.